Great West Life Assurance Co. Can grew its position in Cryolife Inc (NYSE:CRY) by 7.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,728 shares of the medical equipment provider’s stock after acquiring an additional 3,049 shares during the quarter. Great West Life Assurance Co. Can owned 0.12% of Cryolife worth $1,144,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Wells Fargo & Company MN grew its holdings in shares of Cryolife by 6.5% in the third quarter. Wells Fargo & Company MN now owns 63,748 shares of the medical equipment provider’s stock valued at $2,243,000 after purchasing an additional 3,905 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in Cryolife during the third quarter worth about $284,000. Crossmark Global Holdings Inc. purchased a new position in Cryolife during the third quarter worth about $204,000. Bank of New York Mellon Corp boosted its stake in Cryolife by 11.9% during the third quarter. Bank of New York Mellon Corp now owns 459,275 shares of the medical equipment provider’s stock worth $16,166,000 after buying an additional 48,994 shares during the period. Finally, BlackRock Inc. boosted its stake in Cryolife by 5.4% during the third quarter. BlackRock Inc. now owns 5,381,087 shares of the medical equipment provider’s stock worth $189,415,000 after buying an additional 277,486 shares during the period. Institutional investors own 71.34% of the company’s stock.
CRY stock traded down $0.22 during mid-day trading on Friday, hitting $27.55. 225,366 shares of the company were exchanged, compared to its average volume of 230,493. The firm has a market cap of $1.02 billion, a PE ratio of 105.96 and a beta of 0.54. Cryolife Inc has a 12-month low of $21.35 and a 12-month high of $36.05. The company has a debt-to-equity ratio of 0.81, a current ratio of 5.19 and a quick ratio of 3.87.
CRY has been the subject of several research analyst reports. ValuEngine raised shares of Cryolife from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 2nd. Zacks Investment Research lowered shares of Cryolife from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. Northland Securities reaffirmed a “buy” rating and set a $32.00 target price on shares of Cryolife in a research note on Thursday, January 17th. Finally, Needham & Company LLC initiated coverage on shares of Cryolife in a research note on Wednesday, February 27th. They set a “hold” rating and a $29.65 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $32.16.
In other Cryolife news, VP Amy Horton sold 6,666 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $29.15, for a total value of $194,313.90. Following the transaction, the vice president now directly owns 103,713 shares in the company, valued at $3,023,233.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronald D. Mccall sold 6,200 shares of the firm’s stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $29.26, for a total transaction of $181,412.00. Following the transaction, the director now owns 137,699 shares in the company, valued at $4,029,072.74. The disclosure for this sale can be found here. 4.40% of the stock is owned by company insiders.
Cryolife Company Profile
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Further Reading: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.